Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) Assets Average (2016 - 2025)

IGC Pharma (IGC) has disclosed Assets Average for 15 consecutive years, with $8.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average fell 15.63% to $8.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.8 million, a 15.63% decrease, with the full-year FY2025 number at $9.3 million, down 31.13% from a year prior.
  • Assets Average was $8.8 million for Q3 2025 at IGC Pharma, up from $8.3 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $35.2 million in Q2 2021 to a low of $8.3 million in Q2 2025.
  • A 5-year average of $19.1 million and a median of $16.4 million in 2023 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: rose 28.94% in 2021, then tumbled 43.19% in 2024.
  • IGC Pharma's Assets Average stood at $32.6 million in 2021, then crashed by 35.46% to $21.0 million in 2022, then tumbled by 33.94% to $13.9 million in 2023, then fell by 29.96% to $9.7 million in 2024, then fell by 9.06% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Assets Average are $8.8 million (Q3 2025), $8.3 million (Q2 2025), and $8.9 million (Q1 2025).